PL2188289T3 - (7H-pirolo[2,3-D]pirymidyn-4-ylo)-piperazyny jako inhibitory kinaz do leczenia nowotworów i zapalenia - Google Patents

(7H-pirolo[2,3-D]pirymidyn-4-ylo)-piperazyny jako inhibitory kinaz do leczenia nowotworów i zapalenia

Info

Publication number
PL2188289T3
PL2188289T3 PL08782684T PL08782684T PL2188289T3 PL 2188289 T3 PL2188289 T3 PL 2188289T3 PL 08782684 T PL08782684 T PL 08782684T PL 08782684 T PL08782684 T PL 08782684T PL 2188289 T3 PL2188289 T3 PL 2188289T3
Authority
PL
Poland
Prior art keywords
piperazines
pyrrolo
pyrimidin
inflammation
cancer
Prior art date
Application number
PL08782684T
Other languages
English (en)
Inventor
Bryce Alden Harrison
Spencer David Kimball
Ross Mabon
David Brent Rawlins
Dennis S Rice
Michael Victor Voronkov
Yulian Zhang
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of PL2188289T3 publication Critical patent/PL2188289T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL08782684T 2007-08-08 2008-08-08 (7H-pirolo[2,3-D]pirymidyn-4-ylo)-piperazyny jako inhibitory kinaz do leczenia nowotworów i zapalenia PL2188289T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95469807P 2007-08-08 2007-08-08
EP08782684.8A EP2188289B1 (en) 2007-08-08 2008-08-08 (7h-pyrrolo[2,3-d]pyrimidin-4-yl)-piperazines as kinase inhibitors for the treatment of cancer and inflammation
PCT/US2008/072584 WO2009021169A2 (en) 2007-08-08 2008-08-08 (7h-pyrr0l0 [2, 3-d] pyrimidin-4-yl) -piperazines as kinase inhibitors for the treatment of cancer and inflammation

Publications (1)

Publication Number Publication Date
PL2188289T3 true PL2188289T3 (pl) 2016-04-29

Family

ID=39873878

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08782684T PL2188289T3 (pl) 2007-08-08 2008-08-08 (7H-pirolo[2,3-D]pirymidyn-4-ylo)-piperazyny jako inhibitory kinaz do leczenia nowotworów i zapalenia

Country Status (12)

Country Link
US (1) US8507672B2 (pl)
EP (2) EP2597098A1 (pl)
JP (2) JP5406838B2 (pl)
CN (1) CN101772502A (pl)
AU (1) AU2008285388B2 (pl)
CA (1) CA2695857C (pl)
DK (1) DK2188289T3 (pl)
ES (1) ES2557931T3 (pl)
HU (1) HUE025788T2 (pl)
PL (1) PL2188289T3 (pl)
PT (1) PT2188289E (pl)
WO (1) WO2009021169A2 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2297153B1 (en) * 2008-04-21 2015-05-27 Lexicon Pharmaceuticals, Inc. Limk2 inhibitors, compositions comprising them, and methods of their use
CA2742306A1 (en) * 2008-11-03 2010-05-06 Chemocentryx, Inc. Compounds for the treatment of osteoporosis and cancers
JP5690823B2 (ja) * 2009-07-08 2015-03-25 レオ ファーマ アクティーゼルスカブ Ｊａｋ受容体およびタンパク質チロシンキナーゼ阻害薬としての複素環化合物
CA2786730A1 (en) 2010-01-22 2011-07-28 Lexicon Pharmaceuticals, Inc. 5-(1h-pyrazol-5-yl)thiazole-based compounds for the treatment of diseases and disorders of the eye
US9586961B2 (en) * 2010-07-09 2017-03-07 Leo Pharma A/S Homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
CN102372717B (zh) * 2010-08-20 2014-06-18 和记黄埔医药（上海）有限公司 吡咯并嘧啶类化合物及其用途
CN103298817A (zh) * 2011-01-07 2013-09-11 利奥制药有限公司 作为蛋白酪氨酸激酶抑制剂的新磺酰胺哌嗪衍生物及其药物用途
WO2013182612A1 (en) * 2012-06-07 2013-12-12 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
US20150238466A1 (en) * 2012-06-28 2015-08-27 Ramot At Tel-Aviv University Ltd. Lim kinase inhibitors
RU2015102537A (ru) * 2012-06-28 2016-08-20 Эббви Инк. Цианогуанидины и их применение в качестве противовирусных средств
JP6318156B2 (ja) * 2012-09-06 2018-04-25 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼをモジュレートするための化合物および方法、ならびにその指標
WO2014145576A2 (en) 2013-03-15 2014-09-18 Northwestern University Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer
WO2015150337A1 (en) 2014-04-01 2015-10-08 Amakem Nv Lim kinase inhibitors
CN104876933A (zh) * 2015-05-12 2015-09-02 烟台万润药业有限公司 一种含氮杂环酰基哌嗪类化合物及其制备方法与应用
WO2017201187A1 (en) * 2016-05-18 2017-11-23 Virongy, Llc Lim kinase inhibitors
EP3515909A1 (en) * 2016-09-23 2019-07-31 Cellipse Lim kinase inhibitors, pharmaceutical composition and method of use in limk-mediated diseases
CN111620854A (zh) * 2019-02-28 2020-09-04 上海医药工业研究院 4-氨基嘧啶取代的苯基酰胺类化合物及其制备方法
US20220288081A1 (en) * 2019-09-25 2022-09-15 Macquarie University Treatment of excitotoxicity-related conditions
JP7638004B2 (ja) * 2019-09-25 2025-03-03 マッコーリー ユニバーシティー 認知症の治療
EP3915990A1 (en) * 2020-05-26 2021-12-01 Centre National de la Recherche Scientifique 4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridine-1-(2h)-carboxamide derivatives as limk and/or rock kinases inhibitors for use in the treatment of cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136173A (en) 1977-01-31 1979-01-23 American Home Products Corp. Mixed xanthan gum and locust beam gum therapeutic compositions
US5753664A (en) 1995-03-16 1998-05-19 Takeda Chemical Industries, Ltd. Heterocyclic compounds, their production and use
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
WO2002099083A2 (en) 2001-06-05 2002-12-12 Exelixis, Inc. Gfats as modifiers of the p53 pathway and methods of use
WO2004047868A1 (ja) 2002-11-27 2004-06-10 Santen Pharmaceutical Co., Ltd. Limキナーゼ阻害作用を有する化合物を有効成分とする緑内障治療剤
TWI336257B (en) 2003-06-13 2011-01-21 Alcon Inc Ophthalmic compositions containing a synergistic combination of three polymers
AU2004293026B2 (en) * 2003-11-21 2012-01-19 Array Biopharma Inc. AKT protein kinase inhibitors
US20060178388A1 (en) 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
US7423043B2 (en) * 2005-02-18 2008-09-09 Lexicon Pharmaceuticals, Inc. 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
US20080076924A1 (en) * 2006-06-30 2008-03-27 Patrick Betschmann Piperazines as P2X7 antagonists
AU2008240188A1 (en) * 2007-04-13 2008-10-23 Supergen, Inc. Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders

Also Published As

Publication number Publication date
JP2014040432A (ja) 2014-03-06
EP2188289B1 (en) 2015-10-28
EP2597098A1 (en) 2013-05-29
EP2188289A2 (en) 2010-05-26
JP2010535813A (ja) 2010-11-25
CA2695857C (en) 2015-08-04
AU2008285388B2 (en) 2013-09-19
AU2008285388A1 (en) 2009-02-12
JP5406838B2 (ja) 2014-02-05
ES2557931T3 (es) 2016-01-29
US8507672B2 (en) 2013-08-13
CA2695857A1 (en) 2009-02-12
CN101772502A (zh) 2010-07-07
HUE025788T2 (en) 2016-04-28
WO2009021169A3 (en) 2009-04-30
DK2188289T3 (en) 2016-01-25
PT2188289E (pt) 2015-12-21
US20090042893A1 (en) 2009-02-12
WO2009021169A2 (en) 2009-02-12

Similar Documents

Publication Publication Date Title
PT2188289E (pt) (7h-pirrolo[2,3-d]pirimidin-4-il)piperazinas como inibidores de quinases para o tratamento de cancro e de inflamação
HUS2400038I1 (hu) Pirrolo[2,3-d]primidin származékok, mint protein kináz B inhibitorok
IL207224A0 (en) Pyrrolo [2,3-d] pyrimidines and use thereof as tyrosine kinase inhibitors
SMT202000713T1 (it) Pirazolo [1,5-a] pirimidine utili come inibitori dell'atr chinasi per il trattamento di malattie del cancro
ZA201005793B (en) 3h-[1,2,3]triazolo[4,5-d]pyrimidine compounds,their use as mtor kinase and pi3 kinase inhibitors,and their synthesis
IL195731A0 (en) Pyrimidine derivatives useful in the treatment of cancer
EP1945631B8 (en) 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
IL219253A (en) Benzodiazepine inhibiting bromodomain for cancer treatment
EP1945222A4 (en) PYRROLO [2,1-F] [1,2,4] TRIAZIN-4-YLAMINE DERIVATIVES INHIBITORS OF IGF-1R KINASE FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES
PT2073811E (pt) Inibidores de quinase úteis para o tratamento de doenças mieloproliferativas e outras doenças proliferativas
IL202505A0 (en) 2-oxo-3-benzyl-benzoxazol-2-one derivatives and related compounds as met kinase inhibitors for the treatment of tumors
SI2120932T1 (sl) Indazolni derivati kot kinazni inhibitorji za zdravljenje raka
IL212716A0 (en) Thieno [3,2-c] pyridine derivatives as kinase inhibitors for use in the treatment of cancer
HUE037109T2 (hu) Endoxifén rák kezelésében történõ alkalmazásra
IL201209A0 (en) Pyrido [2, 3 - d] pyrimidin - 7 - one compounds as inhibitors of pi3k - alpha for the treatment of cancer
EP2142543B8 (en) Pyrido [2, 3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
PL2358697T3 (pl) Związki izoindolinowe do zastosowania w leczeniu raka
PT3330383T (pt) Grn163l para utiliização como inibidor de telomerase no tratamento de cancro
ZA200902730B (en) Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer
IL206189A (en) Compounds for use in cancer treatment
ZA200810524B (en) Pyrimidine derivatives useful in the treatment of cancer
ZA200803582B (en) 4-(3-Aminopyrazole) Pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
HK1132259A (en) Pyrimidine derivatives useful in the treatment of cancer
HK1123045A (en) 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
HK1145178A (en) Pyrrolo [2, 3-d] pyridines and use thereof as tyrosine kinase inhibitors